Core Viewpoint - Heng Rui Medicine experienced a 5.13% decline in stock price, closing at 63.57 yuan per share, with a total market capitalization of 421.93 billion yuan [1]. Company Overview - Jiangsu Heng Rui Medicine Co., Ltd. is located in Lianyungang, Jiangsu, and was established on April 28, 1997, with its stock listed on October 18, 2000. The company focuses on the research, production, and sales of pharmaceuticals, particularly in the oncology field, covering areas such as kinase inhibitors, antibody-drug conjugates (ADC), tumor immunology, hormone receptor regulation, DNA repair, and supportive therapies [1]. - The company's product portfolio includes anti-tumor drugs, analgesics, and contrast agents, which are used in various medical fields including autoimmune diseases, metabolic diseases, cardiovascular diseases, infectious diseases, respiratory diseases, hematological diseases, pain management, neurological diseases, ophthalmology, and nephrology [1]. - The main revenue composition of the company is as follows: 86.88% from product sales, 12.63% from licensing income, and 0.49% from other sources [1]. Fund Holdings - According to data from major fund holdings, Shangzheng Fund has one fund heavily invested in Heng Rui Medicine. The Shangzheng Zhengtai Balanced Allocation Mixed Fund A (020848) held 40,000 shares in the second quarter, accounting for 7.53% of the fund's net value, making it the third-largest holding. The estimated floating loss today is approximately 137,600 yuan [2]. - The Shangzheng Zhengtai Balanced Allocation Mixed Fund A was established on November 5, 2024, with a latest scale of 27.43 million yuan. Year-to-date returns are 16.7%, ranking 5022 out of 8155 in its category, while cumulative returns since inception are 17.67% [2]. Fund Manager Information - The fund manager of Shangzheng Zhengtai Balanced Allocation Mixed Fund A is Chen Liejiang, who has been in the position for 3 years and 236 days. The total asset size of the fund is 124 million yuan, with the best fund return during his tenure being 121.21% and the worst being 5.47% [3].

Core Viewpoint - Heng Rui Medicine's stock price has shown a significant increase of 40.02% year-to-date, indicating strong market performance despite recent fluctuations in trading volume and net capital outflow [2][3]. Company Overview - Heng Rui Medicine, established on April 28, 1997, and listed on October 18, 2000, is primarily engaged in the research, production, and sales of pharmaceuticals, focusing on oncology and related fields [2]. - The company's product portfolio includes anti-tumor drugs, analgesics, and contrast agents, with applications across various medical conditions such as autoimmune diseases, cardiovascular diseases, and neurological disorders [2]. Financial Performance - For the first half of 2025, Heng Rui Medicine reported a revenue of 15.76 billion yuan, representing a year-on-year growth of 15.88%, and a net profit attributable to shareholders of 4.45 billion yuan, up 29.67% from the previous year [3]. - The company has distributed a total of 9.30 billion yuan in dividends since its A-share listing, with 3.57 billion yuan distributed over the last three years [4]. Shareholder Structure - As of June 30, 2025, the number of shareholders decreased to 364,700, while the average circulating shares per person increased by 12.70% to 17,493 shares [3]. - Major shareholders include Hong Kong Central Clearing Limited, which holds 535 million shares, and various ETFs that have increased their holdings [4].

Core Viewpoint - Heng Rui Medicine's stock price has shown significant growth this year, with a 45.14% increase, indicating strong market performance and investor interest [2]. Company Overview - Jiangsu Heng Rui Medicine Co., Ltd. is primarily engaged in the research, production, and sales of pharmaceuticals, focusing on oncology and covering various therapeutic areas including pain management and cardiovascular diseases [2]. - The company's revenue composition includes oncology (52.12%), neuroscience (15.33%), imaging agents (9.82%), and other therapeutic areas [2]. Financial Performance - For the first half of 2025, Heng Rui Medicine reported a revenue of 15.76 billion yuan, a year-on-year increase of 15.88%, and a net profit of 4.45 billion yuan, up 29.67% year-on-year [3]. - The company has distributed a total of 9.30 billion yuan in dividends since its A-share listing, with 3.57 billion yuan distributed in the last three years [4]. Stock Market Activity - As of August 25, Heng Rui Medicine's stock price was 66.33 yuan per share, with a market capitalization of 440.25 billion yuan [1]. - The stock has seen a net inflow of 123 million yuan from major funds, indicating strong buying interest [1]. Shareholder Information - As of June 30, 2025, the number of shareholders decreased to 364,700, while the average circulating shares per person increased by 12.70% [3]. - Major shareholders include Hong Kong Central Clearing Limited, which increased its holdings by 14.3 million shares [4].